On Oct. 19, Eli Lilly
- Revenues missed analyst estimates by a hair, but EPS exceeded analyst estimates by a penny.
- Cymbalta and Zyprexa were the main revenue drivers.
- EPS growth was primarily driven by improved gross margins.
(Figures in millions, except per-share data)
Income Statement Highlights
Avg. Est. |
Q3 2006 |
Q3 2005 |
Change |
|
---|---|---|---|---|
Sales |
$3,882 |
$3,864 |
$3,601 |
7.3% |
Net Profit |
-- |
$874 |
$794 |
10% |
EPS |
$0.79 |
$0.80 |
$0.73 |
9.6% |
Diluted Shares |
-- |
1,086 |
1,091 |
(0.5%) |
Get back to basics with a look at the income statement.
Margin Checkup
Q3 2006 |
Q3 2005 |
Change* |
|
---|---|---|---|
Gross Margin |
77.73% |
76.52% |
1.21 |
Operating Margin |
27.17% |
25.92% |
1.25 |
Net Margin |
22.61% |
22.06% |
0.55 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Lilly provided no balance sheet data this time around. (Boo!)
Learn the ways of the balance sheet.
Cash Flow Highlights
Lilly also left out any cash flow information. (Hiss!)
Find out why Fools always follow the money.
Related Companies:
-
Wyeth
(NYSE:WYE) -
Abbott Laboratories
(NYSE:ABT) -
Bristol-Myers Squibb
(NYSE:BMY)
Related Foolishness:
Eli Lilly is a Motley Fool Income Investor pick . Find more dynamic dividend payers with a free 30-day trial.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.